Recent treatment and survival trends in older versus younger women with HR-positive HER2-negative metastatic breast cancer in the real-life multicenter French ESME cohort.

Date publication

décembre 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MASSARD Vincent

Tous les auteurs :
Bouteiller F, Gourgou S, Bringuier M, Galvin A, Mailliez A, Bertrand N, Hung M, Frenel JS, Massard V, Bachelot T, Pflumio C, Gonçalves A, Levy C, Bosquet L, Jacot W, Delaloge S, Grinda T, Bellera C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41411883

Résumé

To describe first-line treatments, overall (OS) and real-world progression-free (rwPFS) survival in women with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) following introduction of CDK4/6 inhibitors (CDK4/6i), according to age (<70; 70 +) and diagnostic period (before/after CDK4/6i).

Mots clés

HER2-, Metastatic breast cancer, Older patients, Positive hormone receptors, Real-word data, Survival endpoints

Référence

Eur J Cancer. 2025 12 5;233:116166